{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-031058","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2026-08-04T11:50:16+00:00","discovered_at":"2026-08-04T11:55:00.337428+00:00","generated_at":"2026-08-04T11:55:18.005929+00:00","sec_items":["3.02"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Galectin Therapeutics converts $105.8M debt to equity, eliminating all outstanding notes from Chairman Uihlein","bullets":["Converted $91.0M principal + $14.8M accrued interest ($105.8M total) into 34,376,167 shares at ~$3.07 blended price.","Post-conversion shares outstanding: 100,849,644; Uihlein owns ~44.3% voting power (49.3% including warrants).","Sixth $10M credit facility (Dec 2025) remains undrawn and available; no notes issued under it.","Company must register resale of shares within 180 days per registration rights provisions.","CEO says conversion 'transformative' for balance sheet, strengthens ability to advance belapectin program."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-031058","json":"https://secwatch.observer/filing/0001140361-26-031058.json","markdown":"https://secwatch.observer/filing/0001140361-26-031058.md","text":"https://secwatch.observer/filing/0001140361-26-031058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036126031058/0001140361-26-031058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036126031058/ef20079045_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T11:55:18.005929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}